EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes

Timothy C Chin-See-Chong, Jasper H Kappen, Elizabeth Palmer, Janice A Layhadi iD, Mohamed H Shamji, Johanna P M van der Valk iD

Clinical & Experimental Allergy · 2025-09 · 55 (9) · 773-783

DOI: 10.1111/cea.70084 ↗

At a glance

Übersichtsarbeit in Clinical & Experimental Allergy, published online on 2025-06-03. Written by Timothy C Chin-See-Chong and 5 co-authors. Institution: Department of Pulmonary Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Major MEDLINE topics: Asthma, Desensitization, Immunologic, Anti-Asthmatic Agents. Cited 17 times so far (Crossref); 96 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Asthma is a complex, heterogeneous disease characterised by clinical phenotypes demonstrating distinct and overlapping immunological mechanisms, classified into type‐2 high and type‐2 low asthma endotypes. Both allergic and eosinophilic non‐allergic asthma are driven through an underlying type‐2 high‐endotype, which can be targeted using therapeutic approaches such as allergen‐specific immunotherapy (AIT) for allergic asthma and biologics. AIT demonstrates efficacy for the treatment of allergic asthma. Approved biologics for asthma management include using various interleukin antagonists and anti‐immunoglobulin E, with Tezepelumab offering promising treatments for both type‐2 high and type‐2 low asthma patients. Novel therapeutic candidates, such as Itepekimab and depemokimab, have demonstrated promising results in a Phase 2 clinical trial in moderate‐to‐severe asthma patients.

Subjects

MeSH terms (MEDLINE)

AsthmaDesensitization, ImmunologicAnti-Asthmatic AgentsHumansPhenotypeAntibodies, Monoclonal, Humanized

Author keywords

allergen‐specific immunotherapyasthmabiologicsbiomarkersendotypephenotype

Substances

Anti-Asthmatic AgentsAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Pulmonary Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
  • Department of Pulmonary Diseases, Erasmus Medical Centrum, Rotterdam, the Netherlands.

ORCID profiles: Janice A Layhadi, Johanna P M van der Valk

Cite

APA

Chin-See-Chong, T. C., Kappen, J. H., Palmer, E., Layhadi, J. A., Shamji, M. H., & van der Valk, J. P. M. (2025). Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes. Clinical & Experimental Allergy, 55(9), 773-783. https://doi.org/10.1111/cea.70084

Vancouver

Chin-See-Chong TC, Kappen JH, Palmer E, Layhadi JA, Shamji MH, van der Valk JPM. Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes. Clinical & Experimental Allergy. 2025;55(9):773-783. doi:10.1111/cea.70084

BibTeX
@article{ChinSeeChong2025,
  author = {Chin-See-Chong, Timothy C and Kappen, Jasper H and Palmer, Elizabeth and Layhadi, Janice A and Shamji, Mohamed H and van der Valk, Johanna P M},
  title = {Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  volume = {55},
  number = {9},
  pages = {773--783},
  doi = {10.1111/cea.70084}
}
Start for free →